Biotech firm backs controversial CRISPR challenger

David Cyranoski

Nature, 2017, vol. 541, issue 7638, 447-447

Abstract: What Novozymes might do with the NgAgo protein, claimed by some to be a powerful gene editor, is still unclear.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature.2017.21343 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:541:y:2017:i:7638:d:10.1038_nature.2017.21343

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature.2017.21343

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().